These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18448619)

  • 1. Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.
    Tallmadge RL; Brindley MA; Salmans J; Mealey RH; Maury W; Carpenter S
    Clin Vaccine Immunol; 2008 Jul; 15(7):1138-40. PubMed ID: 18448619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.
    Hammond SA; Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Sep; 262(2):416-30. PubMed ID: 10502520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.
    Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Jul; 259(2):416-27. PubMed ID: 10388665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus.
    Tagmyer TL; Craigo JK; Cook SJ; Issel CJ; Montelaro RC
    J Gen Virol; 2007 Apr; 88(Pt 4):1324-1336. PubMed ID: 17374779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies.
    Grund CH; Lechman ER; Pezzuolo NA; Issel CJ; Montelaro RC
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():435-42. PubMed ID: 8601778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors.
    Lonning SM; Zhang W; Leib SR; McGuire TC
    J Virol; 1999 Apr; 73(4):2762-9. PubMed ID: 10074123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.
    Tagmyer TL; Craigo JK; Cook SJ; Even DL; Issel CJ; Montelaro RC
    J Virol; 2008 Apr; 82(8):4052-63. PubMed ID: 18234792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies.
    Hussain KA; Issel CJ; Schnorr KL; Rwambo PM; Montelaro RC
    J Virol; 1987 Oct; 61(10):2956-61. PubMed ID: 2442410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.
    Rwambo PM; Issel CJ; Adams WV; Hussain KA; Miller M; Montelaro RC
    Arch Virol; 1990; 111(3-4):199-212. PubMed ID: 2162160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.
    Howe L; Leroux C; Issel CJ; Montelaro RC
    J Virol; 2002 Nov; 76(21):10588-97. PubMed ID: 12368301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies.
    Tschetter JR; Byrne KM; Perryman LE; McGuire TC
    Virology; 1997 Apr; 230(2):275-80. PubMed ID: 9143283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Truncation of the Cytoplasmic Tail of Equine Infectious Anemia Virus Increases Virion Production by Improving Env Cleavage and Plasma Membrane Localization.
    Wang XF; Wang YH; Bai B; Zhang M; Chen J; Zhang X; Gao M; Wang X
    J Virol; 2021 Nov; 95(23):e0108721. PubMed ID: 34495693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine.
    Meng Q; Lin Y; Ma J; Ma Y; Zhao L; Li S; Yang K; Zhou J; Shen R; Zhang X; Shao Y
    Viral Immunol; 2012 Dec; 25(6):477-84. PubMed ID: 23171359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Envelope determinants of equine lentiviral vaccine protection.
    Craigo JK; Ezzelarab C; Cook SJ; Chong L; Horohov D; Issel CJ; Montelaro RC
    PLoS One; 2013; 8(6):e66093. PubMed ID: 23785473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.
    Craigo JK; Barnes S; Zhang B; Cook SJ; Howe L; Issel CJ; Montelaro RC
    Retrovirology; 2009 Oct; 6():95. PubMed ID: 19843328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection.
    Mealey RH; Leib SR; Pownder SL; McGuire TC
    J Virol; 2004 Sep; 78(17):9295-305. PubMed ID: 15308724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.
    Hammond SA; Li F; McKeon BM; Cook SJ; Issel CJ; Montelaro RC
    J Virol; 2000 Jul; 74(13):5968-81. PubMed ID: 10846078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine.
    Craigo JK; Ezzelarab C; Cook SJ; Liu C; Horohov D; Issel CJ; Montelaro RC
    PLoS Pathog; 2015 Jan; 11(1):e1004610. PubMed ID: 25569288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication.
    Craigo JK; Leroux C; Howe L; Steckbeck JD; Cook SJ; Issel CJ; Montelaro RC
    J Gen Virol; 2002 Jun; 83(Pt 6):1353-1359. PubMed ID: 12029150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-neutralizing and subclass characteristics of antibody from horses with equine infectious anemia virus.
    O'Rourke KI; Perryman LE; McGuire TC
    Vet Immunol Immunopathol; 1989 Nov; 23(1-2):41-9. PubMed ID: 2559537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.